
The effects of finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, on cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) by history of heart failure were compared in this prespecified analysis of the FIDELIODKD study (HF). Finerenone improved cardiorenal outcome in patients with CKD and T2D in the FIDELIODKD trial, regardless of baseline HF history.
Like
Save
Share